Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Defense

###### Office of the Secretary

# AGENCY:

Assistant Secretary of Defense (Health Affairs), DoD.

# ACTION:

Notice of meeting.

# SUMMARY:

Under the provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix) and the Government in the Sunshine Act of 1976 (5 U.S.C. 552b) the Department of Defense announces that the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel) will meet on March 25, 2010.

# DATES:

The meeting will be held on March 25, 2010, from 8 a.m. to 5 p.m and will be open to the public from 9 a.m. to 5 p.m.

# ADDRESSES:

The meeting will be held at the Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004.

# FOR FURTHER INFORMATION CONTACT:

                        Lieutenant Colonel Thomas Bacon, Designated Federal Officer, Uniform Formulary Beneficiary Advisory Panel, 5111 Leesburg Pike, Skyline 5, Suite 810, Falls Church, VA 22041-3206, Telephone: (703) 681-2890 Fax: (703) 681-1940, E-mail:                         *Baprequests@tma.osd.mil.*

# SUPPLEMENTARY INFORMATION:

## Purpose of Meeting

The Panel will review and comment on recommendations made to the Director, TRICARE Management Activity, by the Pharmacy and Therapeutics Committee regarding the Uniform Formulary.

## Meeting Agenda

Sign-In; Welcome and Opening Remarks; Public Citizen Comments; Scheduled Therapeutic Class Reviews—Basal Insulins; Antihemophilic Factors; Designated Newly Approved Drugs and Drugs recommended for non-formulary placement due to non-compliance with Fiscal Year 2008, National Defense Authorization Act, Section 703; Panel Discussions and Vote, and comments following each therapeutic class review.

## Meeting Accessibility

Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102-3.140 through 102-3.165, and the availability of space this meeting is open to the public from 9 a.m. to 5 p.m. Seating is limited and will be provided only to the first 220 people signing in. All persons must sign in legibly.

## Administrative Work Meeting

Prior to the public meeting the Panel will conduct an Administrative Work Meeting from 8 a.m. to 9 a.m. to discuss administrative matters of the Panel. The Administrative Work Meeting will be held at the Naval Heritage Center, 701 Pennsylvania Avenue, NW., Washington, DC, 20004. Pursuant to 41 CFR 102-3.160, the Administrative Work Meeting will be closed to the public.

## Written Statements

                    Pursuant to 41 CFR 102-3.105(j) and 102-3.140, the public or interested organizations may submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel's Designated Federal Officer. The Designated Federal Officer's contact information can be obtained from the General Services Administration's Federal Advisory Committee Act Database—                    *https://www.fido.gov/​facadatabase/​public.asp.*

                    Written statements that do not pertain to the scheduled meeting of the Panel                           ( print page 10790)                        may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting, then these statements must be submitted no later than 5 business days prior to the meeting in question. The Designated Federal Officer will review all submitted written statements and provide copies to all the committee members.                

## Public Comments

In addition to written statements, the Panel will set aside 1 hour for individuals or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice; but if they still want to address the Panel, then they will be afforded the opportunity to register to address the Panel. The Panel's Designated Federal Officer will have a “Sign-Up Roster” available at the Panel meeting, for registration on a first-come, first-serve basis. Those wishing to address the Panel will be given no more than 5 minutes to present their comments, and at the end of the 1-hour time period no further public comments will be accepted. Anyone who signs up to address the Panel but is unable to do so due to the time limitation may submit their comments in writing; however, they must understand that their written comments may not be reviewed prior to the Panel's deliberation. Accordingly, the Panel recommends that individuals and interested groups consider submitting written statements instead of addressing the Panel.

## Waiver

                    Due to internal DoD difficulties, beyond the control of the Uniform Formulary Beneficiary Advisory Panel or its Designated Federal Officer, the Government was unable to process the                     **Federal Register**                     notice for the March 25, 2010, meeting of the Uniform Formulary Beneficiary Advisory Panel as required by 41 CFR 102-3.150(a). Accordingly, the Committee Management Officer for the Department of Defense, pursuant to 41 CFR 102-3.150(b), waives the 15-calendar day notification requirement.                

Dated: March 3, 2010.

Mitchell S. Bryman,

Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 2010-4954 Filed 3-8-10; 8:45 am]

BILLING CODE 5001-06-P